0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Endocrinology of Zoladex in Postmenopausal Women

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the postmenopausal woman, low plasma oestrogen levels are due to the cessation of ovarian follicular activity, and residual oestrogen is thought to result from the adrenal glands and ovaries, both sources of androgens for peripheral oestrogen synthesis. In a study of 21 postmenopausal women with advanced breast cancer, Zoladex (goserelin), 3.6 mg depot, monthly, had no affect on the adrenal-derived androgens, but a direct effect on ovarian secretion of androgens is thought to have occurred. Thus, in such women, medical adrenalectomy is likely to produce an incomplete suppression of plasma androgens, but its combination with Zoladex may provide a new therapeutic option.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-5105-2
          978-3-318-01977-3
          1663-2818
          1663-2826
          1989
          1989
          02 December 2008
          : 32
          : Suppl 1
          : 209-212
          Affiliations
          aDepartment of Biochemical Endocrinology, Royal Marsden Hospital, London, and bUniversity Department of Clinical Oncology, Regional Radiotherapy Centre, Newcastle General Hospital, Newcastle-upon-Tyne, UK
          Article
          181348 Horm Res 1989;32:209–212
          10.1159/000181348
          2533152
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          Breast Cancer

          Comments

          Comment on this article